Documents to download

The bill would provide new delegated powers to update or amend certain regulations governing the UK’s regulatory framework for medical devices and for human and veterinary medicines. Much of this regulatory framework has come from EU regulations and directives, which the UK has implemented through powers available under the European Communities Act 1972. These powers to update existing legislation will not be available after the end of the transition period. The Government has stated that without the changes brought in by the bill, the existing regulations could only be updated in future through primary legislation.

The bill would also make some additional changes to the regulatory framework for medical devices. These changes would include powers to establish a new system for recording data on such devices and the consolidation of enforcement provisions and new sanctions.

The bill received cross-party support in the House of Commons, with each party agreeing the bill was necessary in the circumstances. However, MPs raised concerns about matters including:

  • the scope of the delegated powers available under the bill;
  • whether it would lead to less regulatory alignment with the EU;
  • why the wording of the bill’s regulation-making powers did not prioritise consideration of patient safety;
  • tackling organ harvesting and other unethical practices; and
  • the potential large policy changes it could lead to, including “hub-and-scope” dispensing.

The Government defended its position on these issues. It said the bill’s delegated powers were limited, and those powers would be subject to sufficient scrutiny. For example, the exercise of most of the delegated powers would require prior consultation with appropriate bodies and would be subject to the draft affirmative process. The Government also said it did not intend to make any bold policy changes without full consultation.

No opposition amendments were made to the bill during its House of Commons stages. However, MPs agreed some government amendments at committee stage. A new clause proposed by the Government was added at report stage. The House of Commons agreed each of these without a vote.


Documents to download

Related posts

  • Acute, primary and community healthcare

    There have been big differences in expenditure across different forms of healthcare for a number of years. In 2024/25, spending on acute care was £74.7bn, compared to £14.5bn on primary care and £13.8bn on community services. Both the 2024 Labour Party manifesto and the subsequent 10 year health plan for England contained an emphasis on shifting towards more care being delivered in local communities rather than in acute settings, dubbed a ‘neighbourhood health service’.

    Acute, primary and community healthcare
  • Myalgic encephalomyelitis (ME): An overview

    Myalgic encephalomyelitis, also known as ME or chronic fatigue syndrome, is a long-term health condition that is estimated to affect over 400,000 people in the UK. It is a fluctuating condition with symptoms including fatigue, sleep problems and brain fog. In 2025 the government published its final delivery plan on ME, which aimed to improve care and support for those with the condition.

    Myalgic encephalomyelitis (ME): An overview
  • Welfare reforms and youth unemployment

    Concerns have been raised about levels of welfare spending in the UK and increasing numbers of young people not in education, employment or training. This briefing sets out statistics, government policy and commentary on welfare and youth employment. This includes the government’s youth guarantee, its ‘Get Britain working’ policies and the interim report by Alan Milburn on young people and work.

    Welfare reforms and youth unemployment